ZERO CANDIDA ANNOUNCES PLANS TO COMPLETE PRECLINICAL STUDIES FOR FDA SUBMISSION BY Q3 2025
Source text: ID:nPred8RMBa
Further company coverage: ZCT.V
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.